Skip to main content
Erschienen in: Der Onkologe 12/2012

01.12.2012 | Leitthema

Chronische lymphatische Leukämie

verfasst von: A. Engelke, C. Müller, Prof. Dr. M. Hallek

Erschienen in: Die Onkologie | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die chronische lymphatische Leukämie (CLL) ist ein niedrig malignes Non-Hodgkin-Lymphom und die häufigste Leukämie der westlichen Welt. Die Erkrankung ist durch einen stadienhaften Verlauf und eine individuell sehr unterschiedliche Prognose gekennzeichnet. Dank intensiver klinischer Forschung ist es gelungen, eine umfassende Diagnosestellung und Ermittlung des Risikoprofils zu ermöglichen und effektivere Therapieoptionen zu etablieren. Chemoimmuntherapien kommen dabei als Standardtherapie für Patienten im fortgeschrittenen Stadium zum Einsatz, während Patienten im frühen Stadium oder ohne krankheitsspezifische Symptome derzeit nur beobachtet werden. Das Einbringen möglichst vieler Patienten in klinische Studien ist wichtig, um für die Zukunft bessere Therapieoptionen in Aussicht stellen zu können. Voraussichtlich werden neben der klinischen Stadieneinteilung neue Scores, Modelle und Methoden, wie die MRD-Bestimmung (MRD: „minimal residual disease“, minimale Resterkrankung) zur Risikobewertung und Therapiebeurteilung an prognostischem Wert gewinnen.
Literatur
1.
Zurück zum Zitat Bahlo J PN, Elter T, Bauer K et al (2011) Proposal of a prognostic score for previously untreated patients with chronic lymphocytic leukemia based on an overall survival analysis of three German Cll Study Group Phase III Trials. ASH Annual Meeting Abstracts 117:2831 Bahlo J PN, Elter T, Bauer K et al (2011) Proposal of a prognostic score for previously untreated patients with chronic lymphocytic leukemia based on an overall survival analysis of three German Cll Study Group Phase III Trials. ASH Annual Meeting Abstracts 117:2831
2.
Zurück zum Zitat Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206PubMedCrossRef Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–206PubMedCrossRef
3.
Zurück zum Zitat Bottcher S, Ritgen M, Fischer K et al (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30:980–988PubMedCrossRef Bottcher S, Ritgen M, Fischer K et al (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30:980–988PubMedCrossRef
4.
Zurück zum Zitat Cimmino A, Calin GA, Fabbri M et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America 102:13944–13949PubMedCrossRef Cimmino A, Calin GA, Fabbri M et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of America 102:13944–13949PubMedCrossRef
5.
Zurück zum Zitat Cui B WG, Yu J, Martinez D et al (2011) Targeting of chronic lymphocytic leukemia B cells with a novel monoclonal antibody to ROR1. ASH Annual Meeting Abstracts 117:984 Cui B WG, Yu J, Martinez D et al (2011) Targeting of chronic lymphocytic leukemia B cells with a novel monoclonal antibody to ROR1. ASH Annual Meeting Abstracts 117:984
6.
Zurück zum Zitat Dohner H, Fischer K, Bentz M et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580–1589PubMed Dohner H, Fischer K, Bentz M et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580–1589PubMed
7.
Zurück zum Zitat Dohner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916PubMedCrossRef Dohner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916PubMedCrossRef
8.
Zurück zum Zitat Egle A SM, Gassner F, Geisberger R et al (2011) A combination of fludarabine/rituximab with escalating doses of lenalidomide in previously untreated Chronic Lymphocytic Leukemia (CLL): the REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory analyses of induction results. ASH Annual Meeting Abstracts 117:292 Egle A SM, Gassner F, Geisberger R et al (2011) A combination of fludarabine/rituximab with escalating doses of lenalidomide in previously untreated Chronic Lymphocytic Leukemia (CLL): the REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory analyses of induction results. ASH Annual Meeting Abstracts 117:292
9.
Zurück zum Zitat Ginaldi L, De Martinis M, Matutes E et al (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51:364–369PubMedCrossRef Ginaldi L, De Martinis M, Matutes E et al (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51:364–369PubMedCrossRef
10.
Zurück zum Zitat Grever MR, Lucas DM, Dewald GW et al (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799–804PubMedCrossRef Grever MR, Lucas DM, Dewald GW et al (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799–804PubMedCrossRef
11.
Zurück zum Zitat Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456PubMedCrossRef Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456PubMedCrossRef
12.
Zurück zum Zitat Hallek M, Pflug N (2011) State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 25:1–9PubMedCrossRef Hallek M, Pflug N (2011) State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 25:1–9PubMedCrossRef
13.
Zurück zum Zitat Hallek M, Wanders L, Ostwald M et al (1996) Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22:439–447PubMedCrossRef Hallek M, Wanders L, Ostwald M et al (1996) Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22:439–447PubMedCrossRef
14.
Zurück zum Zitat Hamblin TJ, Davis Z, Gardiner A et al (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848–1854PubMed Hamblin TJ, Davis Z, Gardiner A et al (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848–1854PubMed
15.
Zurück zum Zitat Heider KH, Kiefer K, Zenz T et al (2011) A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118:4159–4168PubMedCrossRef Heider KH, Kiefer K, Zenz T et al (2011) A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118:4159–4168PubMedCrossRef
16.
Zurück zum Zitat Hoellenriegel J, Meadows SA, Sivina M et al (2011) The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118:3603–3612PubMedCrossRef Hoellenriegel J, Meadows SA, Sivina M et al (2011) The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118:3603–3612PubMedCrossRef
17.
Zurück zum Zitat Howlader N NA, Krapcho M, Neyman N et al (Hrsg) (o J) Seer Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, Md (2012–15-05 17:07) http://seer.cancer.gov/statfacts/html/clyl.html. In: http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012 Howlader N NA, Krapcho M, Neyman N et al (Hrsg) (o J) Seer Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, Md (2012–15-05 17:07) http://​seer.​cancer.​gov/​statfacts/​html/​clyl.​html.​ In: http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012
18.
Zurück zum Zitat James DF BJ, Werner L, Wierda WG et al (2011) Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. ASH Annual Meeting Abstracts 117:291 James DF BJ, Werner L, Wierda WG et al (2011) Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. ASH Annual Meeting Abstracts 117:291
19.
Zurück zum Zitat Melo JV, Catovsky D, Gregory WM et al (1987) The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 65:23–29PubMedCrossRef Melo JV, Catovsky D, Gregory WM et al (1987) The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. IV. Analysis of survival and prognostic features. Br J Haematol 65:23–29PubMedCrossRef
20.
Zurück zum Zitat Moreau EJ, Matutes E, A’hern RP et al (1997) Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 108:378–382PubMed Moreau EJ, Matutes E, A’hern RP et al (1997) Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 108:378–382PubMed
21.
Zurück zum Zitat O’brien S BJ, Blum KA, Furman RR et al (2011) The Bruton’s Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): follow-up of a Phase Ib/II Study. ASH Annual Meeting Abstracts 117:983 O’brien S BJ, Blum KA, Furman RR et al (2011) The Bruton’s Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): follow-up of a Phase Ib/II Study. ASH Annual Meeting Abstracts 117:983
22.
Zurück zum Zitat Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733PubMedCrossRef Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733PubMedCrossRef
23.
Zurück zum Zitat Puente XS, Pinyol M, Quesada V et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101–105PubMedCrossRef Puente XS, Pinyol M, Quesada V et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101–105PubMedCrossRef
24.
Zurück zum Zitat Rai KR (1987) A critical analysis of staging in CLL. In: Gale RP, Rai KR (Hrsg) Chronic lymphocytic leukemia: recent progress and future directions. Liss, New York, S 253–264 Rai KR (1987) A critical analysis of staging in CLL. In: Gale RP, Rai KR (Hrsg) Chronic lymphocytic leukemia: recent progress and future directions. Liss, New York, S 253–264
25.
Zurück zum Zitat Rai KR, Sawitsky A, Cronkite EP et al (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219–234PubMed Rai KR, Sawitsky A, Cronkite EP et al (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219–234PubMed
26.
Zurück zum Zitat Shanafelt TD, Witzig TE, Fink SR et al (2006) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 24:4634–4641PubMedCrossRef Shanafelt TD, Witzig TE, Fink SR et al (2006) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 24:4634–4641PubMedCrossRef
27.
Zurück zum Zitat Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRef Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRef
28.
Zurück zum Zitat Wang L, Lawrence MS, Wan Y et al (2011) SF3B1 and other novel cancer genes in chronic Lymphocytic Leukemia. N Engl J Med Wang L, Lawrence MS, Wan Y et al (2011) SF3B1 and other novel cancer genes in chronic Lymphocytic Leukemia. N Engl J Med
29.
Zurück zum Zitat Wierda WG, Kipps TJ, Mayer J et al (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749–1755PubMedCrossRef Wierda WG, Kipps TJ, Mayer J et al (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749–1755PubMedCrossRef
30.
Zurück zum Zitat Zhang S WC, Fecteau JF, Cui B et al (2011) A Monoclonal Antibody Specifically Targeting CD44 Inhibits B-Cell Chronic Lymphocytic Leukemia Cell Survival In Vitro and In Vivo. ASH Annual Meeting Abstracts 117:927 Zhang S WC, Fecteau JF, Cui B et al (2011) A Monoclonal Antibody Specifically Targeting CD44 Inhibits B-Cell Chronic Lymphocytic Leukemia Cell Survival In Vitro and In Vivo. ASH Annual Meeting Abstracts 117:927
Metadaten
Titel
Chronische lymphatische Leukämie
verfasst von
A. Engelke
C. Müller
Prof. Dr. M. Hallek
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 12/2012
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-012-2341-8

Weitere Artikel der Ausgabe 12/2012

Der Onkologe 12/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.